Calling it a “historic first,” FDA chief Marty Makary ordered every review decision at the agency to start using a new ...

The U.S. FDA has approved treatment with Emrelis for adult patients with previously treated, advanced NSCLC with high c-Met ...

The FDA approved retifanlimab (Zynyz; Incyte) as the first and only first-line treatment for advanced anal cancer, supported ...

The first drug for a rare and difficult-to-treat type of ovarian cancer has been granted accelerated approval by the Food and Drug Administration (FDA). The treatment, called avutometinib plus ...

The FDA has granted fast-track approval to the drug telisotuzumab vedotin (sold as Emrelis) as a first-of-its-kind treatment for certain people who have non-squamous non-small-cell lung cancer.

FDA approves the first treatment for KRAS-mutated recurrent low-grade serous ovarian cancer (LGSOC), offering new hope for ...

The FDA has approved Emrelis to treat adults with locally advanced or metastatic NSCLC with high c-Met protein overexpression.

The U.S. Food and Drug Administration has approved Verastem's combination therapy for patients with a rare type of ovarian ...